To view as a PDF, click here.

Overview

The AMR Industry Alliance is one of the largest private sector coalitions established to provide sustainable solutions to curb antimicrobial resistance (AMR). The AMR Industry Alliance currently includes over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations. Through its members, the AMR Industry Alliance drives the life-sciences industry to curb AMR across four different pillars: (i) appropriate use of antibiotics to reduce the development of AMR with the support of vaccines and diagnostics; (ii) access to quality antibiotics and ensuring new ones are available to all, and improve and accelerate access to diagnostics in low- and middle-income countries; (iii) mitigating the environmental impact of manufacturing,; and (iv) investing in research and science to meet public health needs with new innovative diagnostics and treatments.

As part of its Strategic Plan 2021-2025, the AMR Industry Alliance is pursuing initiatives across each of these four pillars through relevant internal Working Groups. The AMR Industry Alliance is currently seeking proposals to support the work of its Research and Science Working Group. The duration of this consultancy is defined for a period of approximately 2.5 months, starting 4 August 2021 (or as soon as the procurement process is completed) and ending 15 October 2021 when the deliverables have been approved by the AMR Industry Alliance Board. The consultancy will be conducted under the overall guidance of the AMR Industry Alliance Research and Science Working Group Lead and Core Team. The Consultancy will be home-based, from any country.

Background and Objectives of the Consultancy

Over the last years, there have been a number of significant advances toward market incentives, especially pull incentives. However, there remains a need to better understand how regulatory mechanisms can be harmonized to support pull incentives to motivate innovation for antimicrobial resistance (AMR), including the key challenges. Through its ongoing work, the AMR Industry Alliance Research and Science Working Group is seeking to:

• Increase understanding of how innovation for AMR can be fostered through better understanding of current regulations.
• Facilitate collaborations to innovate and bring critically needed antimicrobials to both developed and developing markets, in partnership with the AMR Industry Alliance’s Access Working Group.
• Leverage lessons learned from the COVID-19 pandemic to inform how regulatory science and data sharing can support an improved global regulatory climate for antimicrobials.

Within this context, the Consultant will support the AMR Industry Alliance’s Research and Science Working Group to:

• Undertake a landscape analysis to better understand (i) key regulatory challenges associated with AMR innovation and research and development; (ii) opportunities to improve convergence of the regulatory environment to foster regulatory alignment for innovation, clinical trials and commercialization, including through regulatory-based incentives in middle-income countries with a high AMR footprint (including India and two other target countries, TBD) and through the Tripartite Regulatory Bodies (European Medicines Agency, Food and Drug Administration, and the Pharmaceuticals Medical Devices Agency).

Deliverables and timelines

In line with the objective of the consultancy, the main deliverables and corresponding timelines are outlined below.

• 17 September 2021: Landscape analysis preliminary results
• 30 September 2021: Draft landscape report
• 31 October 2021: Final landscape report

Estimated requirements, expertise and qualifications

The consultant should be a company, an international consulting group, or other type of organization or an individual with proven expertise in:

• Qualitative and quantitative research to inform policy and regulatory change.
• Understanding access to medicines / AMR challenges and the broader global health ecosystem, including actors and funding mechanisms.
• AMR-focused regulatory and policy work in both high- and middle-income countries / low-resource contexts.
• Undertaking consultations with diverse stakeholders to inform research, including private sector actors, global donors, multilateral and not-for-profit organizations.

Proposals will be assessed against these selection criteria.

Proposal content/structure

Proposals should include the sections and elements outlined below.

Section 1: Technical

• The methodology and work plan for addressing the functional requirements set out in the terms of reference. This should include a tentative schedule of the activities outlining the timelines for major action.
• Expertise of the bidder with respect to the objectives of the terms of reference.
• If applicable:
  • Staff dedicated to the project, with lead identified.
  • Expertise of staff involved.
  • CV of the staff.
• Previous, comparable work samples.
• If applicable, indicate intent to apply to RFP for Regulatory Landscape Phase 2.

Section 2: Profile of the bidder

• Location
• Status (individual, private company, etc.)
• Statement of relevant experience (incl. key clients)
• Previous experience with private sector and access to medicine / AMR
• Code of conduct
• Declaration of non-conflict of interest

Section 3: Financial / cost

The bidder is asked to provide a detailed budget to be evaluated in either CHF or USD, including categories related to staff (role, number of days and cost per day), supplies, and travel.

Responding to the Request for Proposal (RFP)

Proposals and requests for additional information regarding this RFP should be submitted by email to Melissa Gong Mitchell, AMR Industry Alliance Secretariat Lead at mmitchell@amrindustryalliance.org. The deadline for submission of proposals in response to this RFP is Friday 23 July 2021. Please note that the AMR Industry Alliance may decide to extend the period to receive proposals, if deemed necessary.